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Abstract
After the initial discovery of activins as important regulators of reproduction, novel and diverse
roles have been unraveled for them. Activins are expressed in various tissues and have a broad
range of activities including the regulation of gonadal function, hormonal homeostasis, growth and
differentiation of musculoskeletal tissues, regulation of growth and metastasis of cancer cells,
proliferation and differentiation of embryonic stem cells, and even higher brain functions. Activins
signal through a combination of type I and II transmembrane serine/threonine kinase receptors.
Activin receptors are shared by multiple transforming growth factor-b (TGF-b) ligands such as
myostatin, growth and differentiation factor-11 and nodal. Thus, although the activity of each ligand
is distinct, they are also redundant, both physiologically and pathologically in vivo. Activin receptors
activated by ligands phosphorylate the receptor-regulated Smads for TGF-b, Smad2 and 3. The
Smad proteins then undergo multimerization with the co-mediator Smad4, and translocate into the
nucleus to regulate the transcription of target genes in cooperation with nuclear cofactors.
Signaling through receptors and Smads is controlled by multiple mechanisms including
phosphorylation and other posttranslational modifications such as sumoylation, which affect potein
localization, stability and transcriptional activity. Non-Smad signaling also plays an important role in
activin signaling. Extracellularly, follistatin and related proteins bind to activins and related TGF-b
ligands, and control the signaling and availability of ligands.
The functions of activins through activin receptors are pleiotrophic, cell type-specific and
contextual, and they are involved in the etiology and pathogenesis of a variety of diseases.
Accordingly, activin signaling may be a target for therapeutic interventions. In this review, we
summarize the current knowledge on activin signaling and discuss the potential roles of this
pathway as a molecular target of therapy for metabolic diseases, musculoskeletal disorders, cancers
and neural damages.
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Signaling of activins and related growth factors 
through activin receptors
Biosynthesis of activin and related growth factors
Activins belong to the transforming growth factor-b (TGF-
b) family of growth and differentiation factors [1,2]. They
form dimers composed of two inhibin b subunits. Four b
subunits have been identified in mammals (bA, bB, bC
and bE), whereas only a single inhibin a-subunit has been
discovered so far. The bA and bB transcripts are found in
nearly all tissues, whereas bC and bE subunits are
expressedpredominantly in the liver. Both b and a subu-
nits are synthesized as precursor polypeptides. After
dimerization of the precursors, prodomains are cleaved by
furin and/or related proprotein convertases in the endo-
plasmic reticulum and a mature dimeric polypeptide is
released. Homodimers of inhibin bA or bB subunits,
activin A and activin B, respectively, or heterodimeric
activin AB exist in various tissues. Inhibins, heterodimeric
proteins composed of an a-subunit linked to b-subunits
by disulfide bonds, act as activin antagonists. In the case
of myostatin, another TGF-b family protein related to
activins, cleavage and maturation of the ligand may occur
extracellularly in a tissue-specific manner [3].
Activin receptors
Activin signals are transmitted through two types of trans-
membrane serine/threonine kinase receptors, type I and
type II activin receptors in target cells [1,4]. Activin recep-
tors are prototypes of single-pass transmembrane serine/
threonine kinases. Intriguingly, activin receptors are
shared by other TGF-b family proteins, such as myostatin,
growth and differentiation factor 11 (GDF11) and nodal.
Therefore, several activities of these ligands are redundant
with those of activins. Myostatin has been characterized as
a skeletal muscle-specific cytokine regulating skeletal
muscle mass [5]. GDF11 is structurally similar to myosta-
tin, and is involved in neurogenesis in the spinal cord and
olfactory bulb [6]. GDF11 also regulates kidney develop-
ment and endocrine pancreas development [7,8]. Nodal
is a central player in patterning the early embryo during
the induction of mesoderm and endoderm [9], and acts as
an authentic mesoderm inducer in mammalian species.
Some of these activities are shared with activins.
Activin type II receptor, ACVR2 or ActRIIA, has been iden-
tified and characterized as a transmembrane serine/threo-
nine kinase for activin A [10]. A second activin type II
receptor, ACVR2B or ActRIIB, has also been identified [4].
In addition, TGF-b type II receptor, BMP type II receptor
and Müllerian duct inhibiting substance type II receptor
specific to each ligand have been characterized [2]. To
date, seven type I receptors, activin receptor-like kinases 1
to 7 (ALK1-7), have been characterized for the TGF-b fam-
ily [11]. Like type II receptors, type I receptors possess a
serine/threonine kinase domain. However, different from
type II receptors, type I receptors have a unique GS
domain near the intracellular juxtamembrane regions pre-
ceding the kinase domain. The amino acid sequences of
L45 loops of type I receptors located between the kinase
subdomains IV and V are responsible for the preference of
Smad proteins and determine the specificity between the
activin/TGF-b subgroup (ALK4, 5, 7) and BMP subgroup
(ALK1, 2, 3, 6) [2,11]. ALK4 is known as activin type IB
receptor, ACVR1B or ActRIB, whereas ALK7 is known as
activin type IC receptor, ACVR1C. ALK4 and ALK7 are type
I receptors for activins and nodal, and ALK4 and ALK5 are
receptors for myostatin and GDF11 (Table S1; additional
file 1) [1,2]. Once activins bind to ActRIIA or ActRIIB, type
I receptors are recruited to the ligand/ActRII complex, and
the GS domains of type I receptors become phosphor-
ylated by ActRII kinases. Activin/TGF-b-specific Smad,
Smad2 and Smad 3, are phosphorylated by activated type
I receptors (Figure 1). In the case of nodal, the co-receptor
Cripto and related factors are required for the complete
activation [9]. Cripto facilitates nodal signaling by bind-
ing to both nodal and activin receptors. Interestingly,
Cripto may also act as an inhibitory factor for activin sig-
naling when overexpressed [12](Table S1; additional
file 1).
A pseudo-receptor BMP and activin membrane-bound
inhibitor, BAMBI, has been identified [13]. BAMBI inter-
acts with multiple type I receptors for TGF-b family lig-
ands and inhibits the formation of the active receptor
signaling complex. Thus, BAMBI serves as an endogenous
dominant negative receptor [13]. BAMBI is characterized
as a b-catenin target in colorectal tumors [14].
Regulation of activin receptors
Regulatory proteins for activin receptors control the sign-
aling activity of activins and related growth factors. A
FYVE domain-containing protein, the Smad anchor for
receptor activation (SARA), interacts with both the type I
receptor and Smads.
Complex formation of activin receptors with SARA and
Smad in EEA-1 positive early endosomes may be an essen-
tial step for efficient activin/TGF-b signaling [15,16].
Activin type II receptors (ActRIIA and ActRIIB) have con-
sensus amino acids for PSD-95/Discs-large/ZO-1 (PDZ)
protein interaction at their COOH-terminus [1]. This
characteristic is unique among receptors of the TGF-b
family [17]. Activin-receptor interacting proteins (ARIPs),
which have PDZ domains, associate with the COOH-ter-
minus of ActRIIs and regulate activin signaling. ARIP1 has
multiple WW and PDZ domains for protein-protein inter-
actions, and regulates the localization of activin receptors
and negatively controls signaling [17]. Intriguingly, ARIP-
1 acts as a scaffold for N-methyl-D-aspartate (NMDA)
receptor activation in hippocampal neurons, and is alsoCell Communication and Signaling 2009, 7:15 http://www.biosignaling.com/content/7/1/15
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known as synaptic scaffolding protein, S-SCAM [18]. A
recent study showed that activin induces long-lasting
NMDA receptor activation by ARIP1 in hippocampal neu-
rons [19]. ARIP2 is a small protein that has one PDZ
domain [20]. Several ARIP2 splicing isoforms exist, and,
depending on the isoform, ARIP2 either augments or
inhibits activin signaling [21]. Gene trapping analysis
identified the RasGAP-binding protein Dok-1, which acts
downstream of receptor tyrosine kinases as an essential
adapter molecule for activin-induced apoptotic signaling
in B cells. Dok-1 interacts simultaneously with activin
receptors and Smads. Stimulation by activin induces asso-
ciation of Dok-1 and Smad3 [22].
Posttranslational modification of the activin/TGF-b recep-
tor is an additional important mechanism for the regula-
tion of receptor activation. The ubiquitin-proteasome
pathway tightly regulates TGF-b family signaling. HECT-
type E3 ubiquitin ligases, Smad ubiquitin regulatory fac-
tor 1 (Smurf1) and Smurf2 have been implicated in Smad
degradation. Smurf1 and Smurf2 bind to TGF-b family
receptors via the inhibitory Smads, Smad6 and Smad7, to
induce their ubiquitin-dependent degradation [23]. In
addition, TGF-b type I receptor is sumoylated in response
to ligand stimulation. Posttranslational receptor sumoyla-
tion, the covalent attachment of a small ubiquitin-like
modifier (SUMO) is required for the kinase activities of
both the TGF-b type I and type II receptors, and enhances
receptor function by facilitating the recruitment and phos-
phorylation of Smad3 [24].
Regulation of activin signaling through Smads
Smad signaling in the cytoplasm and the nucleus is under
tight control. Smads consist of an NH2-terminal MH1 and
a COOH-terminal MH2 domain. The L45 loop of type I
receptors directly interacts with the MH2 domain of recep-
tor-regulated Smad (R-Smad), and determines Smad spe-
cificity [2]. Type I receptors phosphorylate Smads at their
COOH-terminal two serine residues. Smad2 and 3, R-
Smads for activin and TGF-b undergo constant shuttling
Signal transduction through activin receptors Figure 1
Signal transduction through activin receptors. Activin, myostatin and GDF11 signal through type II and type I serine/
threonine kinase receptors. Type IIR is the principal ligand binding receptors, and ligand/typeIIR complexes recruit and associ-
ate with type IR. Type IR is phosphorylated and activated by type IIR kinase. Smad2 and 3, activin/TGF-b specific Smads, are 
phosphorylated by activated type IR. In the nucleus, Smad2/3/4 complexes regulate gene expression with additional transcrip-
tional cofactors. Smad-independent pathway such as MAPK is also activated downstream of activin receptors. Inhibin acts 
antagonistic to activin by forming high affinity complexes with ActRII and betaglycan. Follistatin, myostatin propeptide and 
receptor ectodomain inhibit the activities of activin and related factors in the extracellular space to prevent ligand/receptor 
interaction. Chemical type IR kinase inhibitors act in the cell to disrupt receptor/intracellular signaling.
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between the cytoplasm and nucleus, and the activation of
R-Smads triggers nuclear accumulation [2]. PPM1A may
act as a Smad COOH-terminal phosphatase [25]. Linker
regions between MH1 and MH2 domains of Smads are
phosphorylated by mitogen-activated protein kinase
(MAPK). This phosphorylation enhances the binding of
ubiquitin ligase to Smad, resulting in polyubiquitination
and degradation [26].
Smads have intrinsic DNA-binding activity [2]. However,
to fully activate target genes, Smad physically associates
with a diverse set of DNA-binding cofactors such as CBP/
p300, TGIF, c-Ski and Evi-1 [11]. This characteristic deter-
mines the cell type-specific transcription and complexity
of activin/TGF-b signaling. A number of transcription fac-
tors including forkhead proteins, bHLH family, AP1 fam-
ily, homeodomain protein family and nuclear receptors
act as Smad-interacting transcription factors [2]. Once
activated, Smad complexes recruit additional transcrip-
tional activators or repressors to regulate target genes (Fig-
ure 1).
Negative feedback regulation by the inhibitory Smads,
Smad6 and Smad7 is an important shutoff system for sig-
naling by the TGF-b family including activins [2,11].
Smad-independent activin signaling and receptor crosstalk
In addition to the canonical Smad pathway, activin sign-
aling through activin receptors regulates other intracellu-
lar pathways. p38 MAPK, ERK1/2 and JNK are activated by
activin in a cell type-specific manner [27,28]. For exam-
ple, activin synergizes with basic fibroblast growth factor
to activate tyrosine hydroxylase expression via the ERK1/
2 pathway [27]. Activin negatively regulates the pituitary
transcription factor Pit-1 through p38 MAPK-dependent
and Smad-independent pathways [28]. Independently of
Smad4, ActRIB/Smad2 acts as a co-activator of the canon-
ical Wnt signaling pathway. Upon activation, Smad2
physically interacts with Tcf4, b-catenin and the co-activa-
tor p300 to enhance transcriptional activity of b-catenin/
Tcf4 through the histone acetyltransferase activity of p300
[29]. Transactivation by Smad2 is independent of the
Smad binding element. Furthermore, recent characteriza-
tion revealed that TGF-b stimulates phosphorylation of
BMP-specific Smad1 independently of BMP receptors [30-
32]. Smad-independent activin signaling and receptor
crosstalk increase the complexity of activin/TGF-b signal-
ing.
Ligand binding proteins
Extracellular activin-binding proteins control activin sign-
aling [1]. Follistatin (FST) is a prototype of activin-bind-
ing proteins. FST is a cysteine-rich single chain
glycoprotein that does not possess sequence similarity to
the TGF-b family [33]. Structural analysis of FST with
activin showed that two FST molecules encircle activin,
and neutralize the ligand by burying one-third of its resi-
dues and both type II and type I receptor binding sites [34-
36] (Figure 1). FST not only binds and inhibits activins,
but also binds and neutralizes the actions of myostatin
and GDF11 [1,37]. Mice with a disrupted follistatin gene
have musculoskeletal and cutaneous abnormalities,
reflecting the abnormal signaling of activins, myostatin
and GDF11 [38]. The follistatin-related gene, FLRG, is a
follistatin domain-containing protein structurally similar
to FST [39,40]. Whereas FST has three follistatin domains,
FLRG has only two. Like FST, FLRG binds and neutralizes
activins, myostatin and GDF11 [37,39]. Proteomics anal-
yses indicate that FLRG associates with myostatin in sera
[37]. Although functionally redundant, expression and
transcriptional regulation of FST and FLRG are different
[39-41]. FLRG gene deleted mice show dysregulated glu-
cose metabolism and fat homeostasis [42](see below).
Biological activities and roles of activin signaling 
as a target of therapeutic interventions
After the purification and identification of activins as reg-
ulators of follicle-stimulating hormone secretion from the
anterior pituitary, important roles of activins in the
hypothalamus-pituitary-gonadal axis have been described
[1]. However, activin activity is not limited to reproduc-
tive tissues. Activins and related factors have pleiotropic
actions in extragonadal tissues. In this section, we focus
on selective actions of activins and related growth factors
from a therapeutic point of view.
Activins and their regulators in metabolic disorders
Activin signaling is required for proper development of
the endocrine and exocrine pancreas, and dysregulation
of the activin signaling pathway contributes to the genesis
of metabolic diseases. In human embryonic stem cells,
activin B mediates the induction of homeoprotein Pdx1, a
key regulator of endocrine pancreas development [43].
ActRIIA mutant mice show hypoplasia of the pancreas
and develop diabetes [44]. ActRIIB and Smad2 activity use
the same signaling pathway to regulate pancreas islet for-
mation [45]. ALK7, a type I receptor for activin B, activin
AB and nodal, is expressed abundantly in pancreatic b
cells and adipose tissues, and regulates insulin biosynthe-
sis and secretion [46-48]. Recent characterization revealed
that ALK7 transmits signals of GDF3, another TGF-b fam-
ily member [49,50]. GDF3, ALK7 and co-receptor Cripto
are all expressed in adipose tissues, and Gdf3(-/-) null
mice and ALK7(-/-) null mice showed reduced fat accu-
mulation and resistance to diet-induced obesity [49,50].
The expression of activin receptors, myostatin and their
binding protein FLRG can be modulated in adipose tissue
and skeletal muscle by chronic obesity. In subcutaneous
and visceral fats, myostatin and ActRIIB mRNA levels inCell Communication and Signaling 2009, 7:15 http://www.biosignaling.com/content/7/1/15
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ob/ob mice are 50- to 100-fold higher than that in wild-
type mice [51]. By contrast, FLRG mRNA levels are
increased in subcutaneous fat, but decreased in visceral fat
of ob/ob mice compared to wild-type mice [51]. In
humans, myostatin was shown to increase in skeletal
muscle and plasma of obese and insulin resistant women
[52].
FLRG gene disrupted mice showed an increased pancre-
atic islet number and size, b cell hyperplasia, decreased
visceral fat mass, improved glucose tolerance, and
enhanced insulin sensitivity. This phenotype is caused
through increased signaling by activin or myostatin in a
tissue-specific manner [42].
Myostatin and activin in muscular diseases
Myostatin, the skeletal muscle specific member of the
TGF-b family, restricts muscle growth and determines
skeletal muscle mass [5]. Myostatin signals through
activin type I receptors (Alk4 and 5) and type II receptors
[5]. Mice with a targeted deletion of the myostatin gene
have a 25–30% increased muscle mass resulting from
hypertrophy and hyperplasia [53]. Double muscling phe-
notypes upon inactivation of the myostatin gene have
been observed in cattle, sheep, race dogs, fish and even in
humans [54-59]. Myostatin is regarded as a good drug tar-
get since therapeutics that stimulate skeletal muscle
growth may be useful for muscle-wasting conditions such
as muscular dystrophy, sarcopenia and cachexia. Whereas
activins and TGF-b function in almost every cell type,
myostatin specifically affects skeletal muscle growth.
Thus, targeting myostatin is a rational therapeutic strategy
to increase skeletal muscle mass. Several myostatin inhib-
itors such as monoclonal antibodies and myostatin
propeptide, as well as FST and its derivatives are promis-
ing candidates for the treatment of muscle wasting disor-
ders [60-67] (Table S2; Additional file 2). Skeletal muscle
fibrosis is also ameliorated by myostatin inhibition [68].
The effectiveness of myostatin inhibition has been studied
using various muscular dystrophy animal models. Mono-
clonal antibody-mediated myostatin blockade results in
an increase of muscle mass and absolute muscle strength
in mdx mice, an animal model of Duchenne-type muscu-
lar dystrophy [60]. Muscles in mdx mice with myostatin
inhibition showed less fibrosis, reduced fatty remodeling
and an improved regeneration process [61]. Myostatin cir-
culates in the serum in a latent form complexed with mul-
tiple binding proteins. NH2-terminal myostatin
propeptide is a major myostatin-binding protein and
non-covalently associates with myostatin [5,37]. Myosta-
tin propeptide, stabilized by fusion to IgG-Fc, has been
shown to be effective in ameliorating dystrophic patho-
physiology [62]. Muscle atrophy caused in mutant caveo-
lin-3 transgenic mice, a model of limb-girdle muscular
dystrophy (LGMD) 1C, was reduced dramatically by
crossing these mice with myostatin propeptide transgenic
mice [63]. In calpain 3-deficient LGMD2A model mice,
both muscle mass and muscle force were recovered upon
gene therapy using myostatin propeptide [64]. Myostatin
blockage at an early stage in a model of d-sarcoglycan-defi-
cient muscular dystrophy was effective in reducing muscle
loss and fibrosis, and in improving regeneration [65]. It is
of note that the elimination of myostatin did not suppress
the phenotype of a laminin-a2-deficient mice, but
increased postnatal lethality due to fat loss [69]. Soluble
forms of an extracellular domain of ActRIIB fused with
IgG-Fc may block myostatin effectively in vivo, and have
strong muscle mass increasing activities [70]. In addition
to myostatin, activin and GDF11 are recognized by solu-
ble forms of ActRIIB [71]. FST and FST-derived myostatin
inhibitors are also effective for increasing muscle mass
and ameliorating muscular dystrophy [66,67]. It is worth
noting that neurogenic muscle atrophy caused by amyo-
trophic lateral sclerosis and spinal muscular atrophy may
be ameliorated by myostatin inhibition either by myosta-
tin antibody or follistatin [72,73].
The expression of activin, myostatin, TGF-b, activin recep-
tors, and FST in cardiac muscle is also deregulated in path-
ological conditions such as cardiac failure and
cardiomyopathy [74,75]. However, in contrast to the
observations in skeletal muscle, myostatin does not coun-
teract cardiac hypertrophy or fibrosis [75].
Roles of activin and BMP signaling in osteoporosis and 
bone formation
Although both BMP and activin regulate bone formation,
their modes of action are distinct. BMPs are potent induc-
ers of osteoblast differentiation. Activins are expressed
abundantly in bone tissues, and regulate bone formation
by controlling both osteoblast and osteoclast functions.
Different from the activity of BMP, activins enhance the
receptor activator of NF-kB ligand (RANKL)-mediated
osteoclast differentiation, and act as commitment factors
for osteoclastogenesis [76]. Both antiresorptive and ana-
bolic drugs are useful for the treatment of osteoporosis
[77]. Bisphosphonates, selective estrogen-receptor modu-
lators and estrogen are currently available antiresorptive
drugs, whereas recombinant human parathyroid hor-
mone is an anabolic drug. Intriguingly, the extracellular
domain of ActRIIA stabilized by fusion to IgG-Fc increases
bone mass and strength by activin inhibition, and is a
novel promising agent for osteoporosis in early human
trials [77,78] (Table S2; Additional file 2).
As mentioned above, the extracellular domain of ActRIIB
fused to IgG-Fc increases muscle mass. Thus, two activin
type II receptor decoys have different clinical uses. Con-
sistent with the activity of activin in bone formation,
inhibin A, an activin antagonist, works as an endocrine
stimulator of bone mass in vivo by increasing osteoblast-Cell Communication and Signaling 2009, 7:15 http://www.biosignaling.com/content/7/1/15
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ogenesis [79]. Inhibin antagonizes activin by forming a
complex of ActRIIs and betaglycan [2,4](Figure 1).
Fibrodysplasia ossificans progressive (FOP), a genetic dis-
order of progressive heterotypic ossification, is caused by
missense mutations in ACVR1A (ALK2), a BMP type I
receptor, which increase BMP signaling [80]. A recurrent
activating mutation in the juxtamembrane GS domain of
ACVR1A was reported in sporadic and familial cases of
classic FOP [80]. Thus, the activin and BMP pathway are
therapeutic targets for the treatment of low bone mass.
Roles of activins and related growth factors in cancer
Inhibition of cancer cell growth is one of the activities of
activins in the early phase of cancer development. Facili-
tating activin signaling either by Cripto silencing or FLRG
silencing inhibits human breast cancer cell growth
[81,82](Table S2; Additional file 2). Mutations in several
genes involved in the activin signaling pathway have been
characterized in cancers. Two 8-bp polyadenine tracts of
the ACVR2 gene were targets for frameshift mutations in
gastrointestinal cancers with microsatellite instability
[83]. Somatic ACVR1B gene mutations have been found
in pancreatic carcinoma [84] and Smad2 and Smad4 are
mutated in colorectal and pancreatic carcinomas [85].
Thus, dysregulation of activin receptors and activin/TGF-b
Smads is directly involved in carcinogenesis.
Interestingly, inhibin-deficient mice develop gonadal sex
cord-stromal tumors [86]. They develop adrenal cortical
tumors when gonadectomized. Therefore, inhibins act as
secreted tumor suppressors in gonads and adrenal glands.
Supraphysiological levels of activins in inhibin-deficient
mice are responsible for the development of tumors.
Overproduction of activins was observed in a cachexia-
like wasting syndrome that includes hepatocellular necro-
sis and metastasis [86-88]. Thus, the actions of activin in
tumor development are highly context-dependent.
Myofibroblasts present in tumor stroma facilitate tumor
development and invasion [2]. TGF-b and activin stimu-
late the differentiation of myofibroblasts from mesenchy-
mal progenitors, suggesting the facilitation of invasive
properties of cancers.
Regarding metastasis, inhibition of activin and/or TGF-b
suppresses experimental metastasis to multiple organs
including lung, liver and bone [89,90](Table S2; Addi-
tional file 2). Chemical inhibitors for type I receptor
kinases for activin/TGF-b (ALK4, 5 and 7) are promising
cancer therapies [89,91]. They may offer an option for
preventing tumor angiogenesis, the motility of cancer
cells, fibrosis and metastasis [92].
TGF-b and TGF-b type I receptor are upregulated at the
tumor-bone interface and modulate RANKL-dependent
osteolysis, and TGF-b inhibition reduces mammary
tumor-induced osteolysis [93]. Since activin works as a
cofactor for RANKL, similar to TGF-b, activin may modu-
late osteoclastogenesis in the tumor-bone  interaction.
TGF-b produced by cancer cells has immunosuppressive
effects, resulting in the evasion of cancers from destruc-
tion by the immune system. A novel TGF-b kinase inhibi-
tor reverses this effect, inhibits cell growth and enhances
the immunogenicity of cancer cells [94]. Whether activins
also act as regulators in immunosuppression in cancers
has not yet been determined.
Activities of activins in the brain
Activins and activin receptors are expressed highly in the
central nervous system and have crucial roles in neuronal
development [95,96]. However, compared with classical
neurotrophic factors, our knowledge about the functions
of activins in the brain is limited. Importantly, the expres-
sion of inhibin bA mRNA, which encodes activin A, is
induced by excitatory synaptic input [97,98]. It is induced
in granule cell neurons of the hippocampus by high-fre-
quency synaptic stimuli that produce long term potentia-
tion (LTP). This induction is NMDA receptor-dependent
[97,98]. Activin increases the number of synaptic contacts
by modulating actin dynamics in the spine of the neurons,
which may be responsible for the establishment of LTP
[99]. This modulation is mediated by the classical MAP
kinase cascades via Erk1/2 [99]. Similarly, inhibin bA
mRNA is transiently induced in dentate gyrus neurons
through NMDA receptor activation after unilateral
mechanical brain injury by saline injection [100]. Inhibin
bA mRNA is also induced during amygdala kindling, and
accurately marks excitatory neurons with synaptic altera-
tions from seizures [101].
Accumulating evidence indicates that activin also has neu-
rotrophic and neuroprotective effects on selective neurons
[102]. Treatment with recombinant activin following
ischemic injury rescues neurons from damage [103].
Overexcited neurons are protected by the neurotrophic
effect of basic fibroblast growth factor, which depends on
the induction of activin A [104] (Table S2; Additional file
2). It is also of note that activin and fibroblast growth fac-
tor act in synergy in dopaminergic neurons [27].
Neuronal-specific transgenic approaches using the aCaM-
KII promoter revealed further functions of activins
[105,106]. Hippocampal neurons in aCaMKII promoter-
driven dominant negative ActRIB transgenic mice were
more vulnerable to kainate injection [105]. These mice
also showed a reduced NMDA current with an impaired
LTP. Reciprocally, activin potentiates NMDA receptor-
mediated signaling by forming complexes with activin
receptors, NMDA receptors and Fyn on postsynaptic scaf-
folding proteins [19]. Interestingly, activins tune pre- andCell Communication and Signaling 2009, 7:15 http://www.biosignaling.com/content/7/1/15
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postsynaptic GABAergic transmission affecting anxiety
[107]. aCaMKII promoter-driven activin and FST trans-
genic mice are affected in their anxiety-related behavior by
modulation of their postnatal neurogenesis in the sub-
granular zone of the dentate gyrus in the hippocampus
[106]. Infusion of activin into the dentate gyrus of the hip-
pocampus produces an antidepressant-like effect in the
forced swim test. Conversely, antidepressants such as
fluoxetine and desipramine increase Smad2 phosphoryla-
tion [108]. These data suggest that the activin signaling
pathway may be a novel target for neuroprotection and
psychopharmacological therapy.
Role of activins in embryonic stem cells
Activin A is a potent mesoderm inducer in Xenopus
embryos, and numerous tissues can be differentiated from
Xenopus animal cap cells and embryonic stem cells [109].
A sophisticated strategy to differentiate mouse embryonic
stem cells into insulin-producing cells or other cell types
by activin has been developed [110,111]. Intriguingly,
activin signaling is indispensable to maintain self-renewal
and the stemness of human embryonic stem cells [111].
Activin signaling sustains the expression of pluripotency-
associated genes such as nanog and inhibits BMP signal-
ing, which promotes self-renewal in human embryonic
stem cells [112].
Conclusion
Activin signaling as a target for therapeutic intervention
Although activins were first discovered as powerful factors
to stimulate follicle-stimulating hormone production
from the anterior pituitary, activins act on almost all cell
types and have diverse roles. Furthermore, activin recep-
tors are shared by other TGF-b family members such as
myostatin, GDF11, nodal and a subset of BMPs. The TGF-
b family members are key regulators of myogenesis, neu-
rogenesis and organogenesis, left-right asymmetry and
bone formation. Actions of activins through activin recep-
tors and Smads are pleiotropic and context-dependent,
and alterations in signaling through activin receptors are
the cause of a variety of disorders. In this review, we
focused on recently characterized aspects of activin signal-
ing in relationship to metabolic diseases, musculoskeletal
diseases, cancers and neuroprotection.
Various strategies have been designed for the inhibition of
activin signaling through receptors. Soluble forms of the
extracellular domains of activin receptors, FST and related
ligand binding proteins, chemical kinase inhibitors for
activin receptors, and siRNAs either for ligand or signaling
molecules interfere with activin signaling. Intriguingly,
histone deacetylase inhibitors or nitric oxide have been
demonstrated to inhibit the progression of muscular dys-
trophy in a mouse model by transcriptional activation of
FST [113,114].
In muscle wasting disorders, the inhibition of myostatin
is a possible therapeutic strategy. Soluble ActRIIB-Fc, FST
and its derivatives, myostatin propeptide, monoclonal
myostatin antibodies and myostatin siRNA are myostatin
inhibitors that have been shown to be beneficial for pre-
venting muscle loss. Cachexia from cancers and neuro-
genic muscle atrophy are also targets for myostatin
inhibition [72,73,115](Table S2; Additional file 2).
In cancers, activins have multiple roles such as regulation
of cancer cell growth, promotion of organ-specific cancer
progression and metastasis. Soluble ActRIIA-Fc is a novel
promising drug for osteoporosis, cancer-related bone loss
and cachexia [77,78,88]. Activin also has neuroprotective
functions, and the augmentation of activins may have
favorable protective effects on neurons (Table S2; Addi-
tional file 2).
Although targeting activin and related factors may
become part of future therapies, given the complexity of
their action, some side-effects of such therapies are cer-
tainly possible. The dysregulation of activin may affect
functions of gonads and adipose tissues [4,42]. It is also
possible that activation or targeting activin/TGF-b may in
some contexts cause uncontrollable tumor growth or det-
rimental cellular apoptosis [22,86].
Once promising proteins or chemicals targeting activin
signaling are discovered, methods of the drug delivery sys-
tem are important issues for effective treatment. The stabi-
lization of peptides by fusion with IgG-Fc or other stable
proteins is a strategy for targeting activin signaling. Deliv-
ery of genes by adeno-associated viral vectors is also
potentially promising [64,116]. Finally, nanoparticles
such as liposomes and atellocollagen are efficient delivery
vehicles for siRNA and proteins [117], and may be useful
in delivering agents that target activin signaling.
In summary, therapeutic interventions targeted to signal-
ing through activin receptors may provide novel strategies
for the development of effective treatments against a vari-
ety of diseases.
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